TrialArthritis & rheumatology (Hoboken, N.J.)2016

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.

Joel M Kremer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.